Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

G. Wang, Y. He, Y. Sun, W. Wang, X. Qian, X. Yu, Y. Pan

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Numerous inherent and acquired genetic alterations have been demonstrated with resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy in metastatic colorectal cancer (mCRC) patients. Although the common oncogenic driver mutations identified include KRAS, NRAS, BRAF, and PI3K, recent studies report a vital role played by human epithelial growth factor receptor-2 (HER2) amplification in acquired resistance to anti-EGFR therapy. HER2 amplification has been associated with poor prognosis in many malignancies including breast and gastric cancer and is also a negative predictor of anti-EGFR therapy. Given the relevance of HER2 amplification in conferring an anti-EGFR resistance, this paper reviews the prevalence of HER2 amplification in mCRC while exploring the prognostic and predictive values of this biomarker. Further, we also discuss the results of the studies that explored the utilization of anti-HER2-targeted therapies in mCRC. HER2-directed therapies have the ability to change the treatment algorithm in clinically relevant small subset of patients with HER2-amplified mCRC.

Original languageEnglish
Pages (from-to)813-822
Number of pages10
JournalClinical and Translational Oncology
Volume22
Issue number6
DOIs
StatePublished - Jun 1 2020

Keywords

  • Amplification
  • Anti-EGFR resistance
  • Biomarker
  • HER2
  • Metastatic colorectal cancer
  • Targeted therapies

Fingerprint

Dive into the research topics of 'Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this